JMS CO., LTD.
7702・Standard Market・Precision Instruments
Japan
Core segment of the JMS Group responsible for the manufacture and sale of medical devices and pharmaceuticals in Japan
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment revenue (full year FY2026, ending March 2026) | ¥44,759 million | ¥46,030 million | ↓ |
| Segment profit (full year FY2026, ending March 2026) | ¥949 million | ¥1,483 million | ↓ |
| Segment assets (end of FY2026, ending March 2026) | ¥57,460 million | ¥56,397 million | ↑ |
| Depreciation expense (full year FY2026, ending March 2026) | ¥1,710 million | ¥1,706 million | — |
| Increase in property, plant and equipment and intangible assets (full year FY2026, ending March 2026) | ¥1,852 million | ¥1,649 million | ↑ |
Business Details
This domestic segment is handled by JMS Co., Ltd. itself. It manufactures and sells medical devices and pharmaceuticals across four fields: Infusion and Nutrition Products, Dialysis Products, Surgical Treatment, and Blood and Cell fields. It positions the Closed System for Drug Preparation and Administration and Feeding and Swallowing Related Products as focus products, providing products and services on a total basis to domestic medical institutions. It also collaborates with equity-method affiliates to build its business foundation in the domestic medical market.
Recent Overview
While Feeding and Swallowing Related Products and the Closed System remained solid, profit declined sharply due to revenue decline in acute blood purification devices and others plus increased expenses
In the Japan segment for FY2026 (ending March 2026), sales of the Closed System for Drug Preparation and Administration and Feeding and Swallowing Related Products continued to grow, while sales of acute blood purification devices and hemodialysis devices for China declined, resulting in net sales of ¥44,759 million (down 2.8% year on year). Segment profit was held to ¥949 million (down 36.0% year on year) due to the impact of the revenue decline in addition to increases in commission fees, R&D expenses, and other costs. As a subsequent event, in April 2026 the Board of Directors resolved to construct a new head office building at the Hiroshima City head office site (construction to begin February 2027, completion scheduled for August 2031), and increased capital expenditure is expected going forward.
Key Products
Growth Drivers
- Continued sales growth of the Closed System for Drug Preparation and Administration (expanding domestic share and accelerating overseas expansion)
- Increased sales due to expanding demand for Feeding and Swallowing Related Products
- Absorbing cost increases through promotion of price pass-through and thorough cost reduction
- Realizing the results of structural reform and growth strategy as the final year of the Medium-Term Management Plan 2027
- Strengthening R&D functions and enhancing head office functions through the construction of the new head office building
Risks
- Risk of revenue decline due to decreased sales of certain products such as acute blood purification devices and hemodialysis devices for China
- Profit pressure from increased costs such as commission fees and R&D expenses (segment profit down 36.0% year on year in FY2026, ending March 2026)
- Accelerating cost-reduction pressure on medical devices due to continued reductions in medical service fees, among other factors
- Decreased sales of mature products such as medical gloves and urinary/drainage-related products
- Increased financial burden from large-scale capital expenditure associated with construction of the new head office building (construction to begin February 2027, completion scheduled for August 2031)
Last updated: June 22, 2026